-
Anesthesiology May 2022
Topics: Cerebrovascular Circulation; Microcirculation; Norepinephrine; Vasoconstrictor Agents
PubMed: 35157752
DOI: 10.1097/ALN.0000000000004149 -
Anesthesiology Feb 2022
Topics: Fluid Therapy; Vasoconstrictor Agents
PubMed: 34816279
DOI: 10.1097/ALN.0000000000004062 -
Anesthesiology Feb 2022
Topics: Fluid Therapy; Vasoconstrictor Agents
PubMed: 34816275
DOI: 10.1097/ALN.0000000000004063 -
Critical Care Nurse Feb 2021
Topics: Critical Care; Enteral Nutrition; Humans; Vasoconstrictor Agents
PubMed: 33560430
DOI: 10.4037/ccn2021779 -
Anesthesia Progress 1992Addition of a vasoconstrictor to a local anesthetic may have several beneficial effects: a decrease in the peak plasma concentration of the local anesthetic agent,... (Review)
Review
Addition of a vasoconstrictor to a local anesthetic may have several beneficial effects: a decrease in the peak plasma concentration of the local anesthetic agent, increase in the duration and the quality of anesthesia, reduction of the minimum concentration of anesthetic needed for nerve block, and decrease of blood loss during surgical procedures. The addition of a vasoconstrictor to a local anesthetic may also have detrimental effects. A review of the literature indicates that vasoconstrictor concentrations in local anesthetics marketed for dental use in the United States are not always optimal to achieve the purposes for which they are added. In most cases, a reduced concentration of vasoconstrictor could achieve the same goal as the marketed higher concentration, with less side-effect liability.
Topics: Amides; Anesthesia, Dental; Anesthesia, Local; Anesthetics, Local; Blood Loss, Surgical; Drug Interactions; Humans; Ropivacaine; Vasoconstrictor Agents
PubMed: 8250339
DOI: No ID Found -
Cleveland Clinic Journal of Medicine Oct 2023
Topics: Humans; Midodrine; Vasoconstrictor Agents; Shock, Septic; Administration, Intravenous; Retrospective Studies
PubMed: 37783502
DOI: 10.3949/ccjm.90a.23040 -
Doklady Biological Sciences :... 2012
Topics: Animals; Female; Kidney; Potassium; Rats; Rats, Wistar; Vasoconstrictor Agents; Vasotocin
PubMed: 22760611
DOI: 10.1134/S0012496612030106 -
Annals of the American Thoracic Society Nov 2023
Topics: Humans; Adult; Vasoconstrictor Agents; Critical Illness; Hypotension; Intensive Care Units
PubMed: 37590119
DOI: 10.1513/AnnalsATS.202306-540RL -
Burns : Journal of the International... Sep 2015Clysis is the subcutaneous or subdermal injection of a vasopressor containing fluid, with or without local anaesthetic agent, and has been used to limit blood loss in... (Meta-Analysis)
Meta-Analysis Review
AIM
Clysis is the subcutaneous or subdermal injection of a vasopressor containing fluid, with or without local anaesthetic agent, and has been used to limit blood loss in patients undergoing surgical burn management. In this systematic review and meta-analysis we aimed to determine the impact of clysis of a vasoconstrictor on burn patient outcomes.
METHODS
We conducted a systematic review to identify trials investigating clysis in burn patients undergoing debridement and/or skin grafting. For each eligible trial we aimed to extract the outcomes of perioperative blood loss, blood transfusion, duration of surgery, graft success and healing time, inflammatory response, sepsis, mortality, duration of hospital stay, catecholamine levels and cardiovascular effects in both the short (<72h) and long term (30 days) after surgery.
RESULTS
From 443 citations, we selected 39 for full-text evaluation, and identified 10 eligible trials. Due to a lack of reporting on outcomes of interest, meta-analysis could only be conducted for the outcome of red blood cell (RBC) units transfused per patient. Patients receiving clysis (n=222) were transfused 1.89 less units (95% CI -2.12 to -1.66) as compared to those not receiving clysis, although this was associated with a high degree of heterogeneity (I(2)=88%).
CONCLUSION
Few studies have adequately evaluated the impact of clysis in burn surgery on patient important outcomes such mortality, duration of surgery and graft success. These results suggest clysis may reduce the need for blood transfusion but additional high quality research is required.
Topics: Blood Loss, Surgical; Burns; Debridement; Hemostasis, Surgical; Humans; Injections, Subcutaneous; Operative Time; Skin Transplantation; Treatment Outcome; Vasoconstrictor Agents
PubMed: 26117275
DOI: 10.1016/j.burns.2015.03.010 -
Cardiology in Review 2012Vasopressors are a heterogeneous potent class of medications designed to increase blood pressure in emergent hypotensive situations. The goal of therapy is to increase... (Review)
Review
Vasopressors are a heterogeneous potent class of medications designed to increase blood pressure in emergent hypotensive situations. The goal of therapy is to increase blood pressure and maintain adequate perfusion, allowing nutrient and oxygen delivery to vital organs. Norepinephrine, phenylephrine, dopamine, epinephrine, and vasopressin are five vasopressors available in the United States. All vasopressors, with the exception of vasopressin, are titratable and dosed on a continuum according to clinical effect. With their different clinical features, adverse effects, and range of potency, the clinical situation usually guides therapy. Outcome data comparing different vasopressors have not demonstrated a clear mortality benefit of any one vasopressor over another, and physician preference also guides therapy. Norepinephrine, nonetheless, remains one of the preferred choices for a variety of hypotensive states, including cardiogenic and septic shock.
Topics: Adult; Drug Interactions; Humans; Hypotension; Shock; Vasoconstrictor Agents
PubMed: 22318007
DOI: 10.1097/CRD.0b013e31824e2294